TP53 and B-cell chronic lymphocytic leukemia: The mutational status of the variable portion of the immunoglobulin gene (IGHV) [6], chromosome 17p deletion as detected by fluorescence in situ hybridization (FISH) [7] and TP53 gene mutations [8] represent powerful prognostic/predictive factors commonly used to stratify CLL patients into different risk groups in the era of chemoimmunotherapy [5, 9–10].